The BMAL2 gene encodes a member of the bHLH-PAS family of transcription factors, which control diverse physiological processes including circadian rhythms. We identified four novel human BMAL2 transcripts that differ by alternative splicing within their N-terminal regions.
BMAL2 (13, 16, 25, 28, 29) . However, the functional consequences of these post-transcriptional
variations have yet to be reported.
The aim of this study was to compare the abilities of human BMAL2 splice and start site variants to activate gene transcription. In this work, we identified four novel human BMAL2 transcripts that differed by alternative splicing in their N-terminal regions. Divergent expression of these and previously reported transcripts was observed among human tissues. The functional consequences of alternative splicing and alternative translation initiation site usage were assessed using luciferase reporter gene constructs that contained one of three promoters, namely those of the mouse period1 (mPer1), mouse vasopressin (mAVP), and human plasminogen activator inhibitor-1 (hPAI-1) genes. These promoters were selected based on their relevance in diverse physiological processes controlled by circadian clocks. While PER1 is a core component of the circadian autoregulatory feedback loop, AVP and PAI-1 are rhythmic outputs from central and peripheral clocks, respectively. Vasopressinergic efferent projections from the suprachiasmatic nuclei to the paraventricular and dorsomedial nuclei of the hypothalamus inhibit corticosterone release in a circadian manner (3, 18) . Diurnal variation in circulating PAI-1 levels may underlie both increased incidence of acute myocardial infarction and decreased efficacy of thrombolytic therapy in the morning (1, 6, 22) . Our results establish alternative splicing as a potentially important regulatory mechanism capable of influencing the amplitudes of both central and peripheral clocks.
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METHODS

Cloning of hBMAL2 Splice and Start Site Variants
Full length human BMAL2 cDNAs were cloned by RT-PCR from primary cultures of human umbilical vein endothelial cells using hBMAL2 forward primer 1 (5'-TGAGAATTCGACCAAGTGGCTCCTGCGATG-3') and hBMAL2 reverse primer 1 (5'-CAAGGATCCGAGGGTCCACTGGATGTCACT-3'). Resulting amplicons were digested with EcoR I and BamH I and cloned into pcDNA3.1/Myc-His(-)A (Invitrogen). This placed an in-frame C-terminal Myc-His tag on each protein except hBMAL2f and hBMAL2b W309*.
To place this tag in-frame for hBMAL2f protein, hBMAL2f cDNA was amplified by PCR using a forward primer complementary to the T7 site on pcDNA3.1/Myc-His(-)A and hBMAL2 reverse primer 2 (5'-TGGTGGAATTCGATTCTTTTCAGTTTGGTATGA-3'), digested with EcoR I, and religated into pcDNA3.1/Myc-His(-)A. To generate hBMAL2b∆N, g∆N, and i∆N expression plasmids, hBMAL2b,g,i cDNAs were amplified by PCR using hBMAL2 forward primer 2 (5'-GCGTGAATTCAGGGACAAGACCAACAGCTATG-3') and hBMAL2 reverse primer 1, digested with EcoR I and BamH I, and religated into pcDNA3.1/Myc-His(-)A. To generate hBMAL2g∆C and i∆C expression plasmids, Bgl II fragments encoding the N-termini of hBMAL2g,i were obtained from our hBMAL2g,i expression plasmids and ligated into a Bgl II fragment encoding the C-terminus of hBMAL2b W309* obtained from our hBMAL2b W309* expression plasmid. Expression plasmids encoding hBMAL2g (i.e. hCLIF), mCLOCK, mPER1, mPER2, mCRY1, and mCRY2 have been described previously (9, 21, 25) . All constructs were verified by chain termination sequencing.
Comparison of hBMAL1 and hBMAL2 Expression by RT-PCR
First-strand cDNA preparations from sixteen human tissues were obtained from Clontech.
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Total RNA was extracted from human aortic smooth muscle and endothelial cells (Clonetics), human coronary artery endothelial cells derived from hypertrophied human hearts explanted during heart transplantation, and human umbilical vein endothelial cells derived from recently birthed human umbilical cords, using a RNeasy Mini Kit (Promega). All tissues were collected in accordance with protocols approved by the Vanderbilt University Institutional Review Board.
From these templates, cDNA encoding the variable N-terminal region of hBMAL2 was amplified by (RT)-PCR using either an Advantage 2 PCR Kit (Clontech) or a Titanium 1-Step RT-PCR Kit (Clontech) and the combination of hBMAL2 forward primer 1 and hBMAL2 reverse primer 3 (5'-CTTTTCAGTTTGGCTATGAGCTTCT-3'). hBMAL1 was amplified using primers 5'-GAACGGGGAAATCAGGGTGAAATCT-3' and 5'-TTGGTCCAAGGGTTCATGAAACTGA-3'. hGAPDH was amplified using primers 5'-GATGACATCAAGAAGGTGGTGAAGC-3' and 5'-TTCGTTGTCATACCAGGAAATGAGC-3'. The identities of all resulting amplicons were confirmed by restriction digest, as well as by direct cloning and chain termination sequencing.
Transfection Studies / Luciferase Reporter Assays
Human embryonic kidney 293 (HEK 293) cells and bovine aortic endothelial cells (BAECs) were plated in twelve-well dishes and transfected with 100 ng luciferase reporter gene construct and 400 ng each cytomegalovirus promoter-containing expression construct using Lipofectamine Plus (Invitrogen) according to the manufacturer's instructions. The total amount of expression plasmid transfected in each experiment was kept constant by addition of varying amounts of empty vector. To correct for potential variation in transfection efficiency, we co-transfected 50 ng pRL-CMV (Promega) in all experiments. Reporter constructs were as follows: mPer1-Luc contained three E-boxes in a 2.0 kb fragment of the mPer1 promoter (9), mAVP-Luc contained
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C-00541-2001.R1, pg. 7 one E-box in a 200 bp fragment of the mAVP promoter (17), and hPAI-1-Luc contained two E-boxes in an 800 bp fragment of the hPAI-1 promoter (38). The mPer1 and mAVP promoters were studied in HEK 293 cells, while the hPAI-1 promoter was studied in BAECs. Cells were deprived of serum at 24 hr after transfection and lysed with Passive Lysis Buffer (Promega) at 48 hr after transfection. Firefly and Renilla luciferase activities were sequentially assayed with a Dual-Luciferase Reporter Assay Kit (Promega). The ratio of firefly to Renilla luciferase activity then served as a measure of normalized luciferase activity for each sample. This ratio was both cell passage-and batch-dependent. For this reason, we expressed the data from each experiment in terms of mean (± SEM) fold induction of normalized luciferase activity, setting those samples cotransfected only with empty expression vector and reporter plasmids as the baseline. Each experiment was transfected on at least three different occasions and each such transfection was completed at least in quadruplicate. Statistical analyses were performed using Student's t test, with significance defined as P < 0.05 for a two-tailed distribution. Equal expression of each transfected hBMAL2 isoform was verified by western blot using an anti-Myc HRP-conjugated antibody (Invitrogen) and chemiluminescent detection using ECL Plus reagents (Amersham Pharmacia).
Immunohistochemistry
BAECs were plated in two-well chamber slides and transfected with hBMAL2 and mCLOCK expression plasmids as described above. Forty-eight hours after transfection, cells were washed twice with phosphate-buffered saline (PBS), fixed with 10% formalin (20 min), washed with PBS / 0.1% Triton X-100 (PBST), and blocked with 10% fetal bovine serum in PBST (20 min).
Mouse anti-Myc IgG (kindly provided by Lee Limbird) was applied in blocking buffer for 1 hr. 
RESULTS
Identification of hBMAL2 Splice and Start Site Variants
We cloned hBMAL2 cDNAs from primary cultures of human umbilical vein endothelial cells (HUVECs) via RT-PCR using primers complementary to sequences flanking the translation initiation site of exon 1 and the termination site of exon 18. By this method, five wild type hBMAL2 cDNAs were identified. These clones encoded four novel splice variants, as well as the splice variant previously reported as hBMAL2b (29). Addition of these four novel splice variants to the existing catalogue of hBMAL2 isoforms increased the total number of known hBMAL2 splice variants to nine.
To facilitate classification of both novel and known hBMAL2 splice and start-site variants, a standardized nomenclature was developed based on that proposed by Okano et al (29).
Consistent with this terminology, isoforms previously reported as hBMAL2, hMOP9, or hCLIF (13, 16, 25, 29) , as well as those first identified in this work, were ordered by length and designated hBMAL2a-i (Fig. 1) . Alignment of these sequences with a human genomic database allowed for localization of the exon-intron boundaries of the hBmal2 gene on chromosome 12p2.2 (Table 1) .
Splice variants of hBMAL2 are each composed of a variable N-terminal region (exons [1] [2] [3] [4] [5] followed by thirteen invariant exons (exons 6-18) that, with the exception of hBMAL2f, encode the defining bHLH, PAS-A, PAS-B, and C-terminal domains of hBMAL2. Within the variable Introduction of a frameshift and premature stop codon by means of alternative splicing is not without precedent. Indeed, alternative splicing at the border of the first PAS domain of mouse BMAL1 has been shown to introduce a frameshift and subsequent premature stop codon such that mBMAL1g' lacks both PAS-A and PAS-B domains (41).
Two newly identified transcripts encoding hBMAL2h and hBMAL2i delete exons 3-5 and instead differ according to exon 1 length. Corresponding isoforms termed hMOP9-Short and hBMAL2 (the latter having no alphabetic suffix in this case), which also delete exons 3-5 but use an alternative translation initiation site, were cloned previously from human brain by Ikeda et al (16) and Hogenesch et al (13) .
As indicated above, two translation initiation sites have been described for hBMAL2.
Located in exons 1 and 2, these competing initiation sites each share 7 of 10 bp with the Kozak consensus sequence, including the requisite purine at position -3 bp (exon 1, CCTGCG ATGG; exon 2, ACAGCT ATGG; consensus, GCCRCC ATGG, R = A/G (20)). In the present study, the translation initiation site of exon 1 was selected as the standard for comparison. Variants of hBMAL2b,e and hBMAL2h,i that utilize the translation initiation site of exon 2 have been reported previously as hMOP9-Long and hMOP9-Short / hBMAL2, respectively (13, 16) .
In addition, a novel point mutation was identified in one of many hBMAL2b clones derived from our pooled multiple-donor primary cultures of HUVECs and named hBMAL2b W309*.
In this clone, substitution of guanine for adenine at the wobble position of codon 309 introduced a premature termination signal between the PAS-A and PAS-B domains of hBMAL2b. Similar truncations of the PAS-B and C-terminal domains of human BMAL1 (e.g. hBMAL1c (15) ) and
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in not yet known.
Tissue Distribution of hBMAL2 Splice Variants
Differential expression of the variable N-terminal region of hBMAL2 and an invariant region Although nine splice variants of hBMAL2 have been described, these results indicated that four splice variants of hBMAL2 predominate in vivo. These four splice variants resulted from differential utilization of early vs. late exon 1 / intron 1 splice junctions and either deletion or insertion of exon 3. In general, splice variants containing exon 1-Short were more prevalent than those containing exon 1-Long, while deletion was more common than insertion of exon 3.
That is, the relative intensities of observed hBMAL2 amplicons roughly followed the series:
hBMAL2i > hBMAL2b > hBMAL2e > hBMAL2h. Splice variants containing exons 4 or 5
were not detected in human tissues by this method.
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Expression of hBMAL2 was observed in fifteen of sixteen human tissues examined. However, both the total concentrations of hBMAL2 and the relative concentrations of specific hBMAL2 splice variants differed among tissues. For example, hBMAL2i was expressed most intensely in brain, heart, lung, placenta, and liver, while hBMAL2b expression varied greatly in these tissues with strong expression in placenta, moderate expression in lung and liver, and weak expression in brain and heart. hBMAL2e was expressed strongly in placenta and weakly in brain, lung, liver, spleen, colon, and skeletal muscle. hBMAL2h was expressed very weakly exclusively in brain, heart, lung, placenta, liver, pancreas, and ovary.
Expression of hBMAL1 was observed in all human tissues examined, with strong expression in brain, heart, lung, placenta, liver, kidney, spleen, and pancreas; moderate expression in thymus, leukocytes, and skeletal muscle; and weak expression in digestive and reproductive organs.
Expression of hGAPDH was invariant.
To further identify potential molecular components of a vascular circadian clock (25, 27), 
Activation Capacities of hBMAL2 Splice and Start Site Variants
The relative abilities of hBMAL2 splice and start site variants to activate gene transcription were compared using luciferase reporter gene constructs that contained one of three diurnally regulated promoters, namely those of the mPer1, mAVP, and hPAI-1 genes. First we assessed the functional consequences of alternative splicing of exons 3-5 for hBMAL2 isoforms derived from transcripts that insert exon 1-Short and utilize its early translation initiation site (Fig. 4) . In the absence of mCLOCK overexpression, hBMAL2b, g, or i overexpression mildly induced luciferase reporter gene transcription by 2.6-, 2.1-, or 1.8-fold, respectively (P < 0.001 for each isoform). In the presence of mCLOCK overexpression however, distinct activation capacities were revealed for each mCLOCK:hBMAL2b, g, or i heterodimer. Although hBMAL2i lacked exons 3-5, Taken together, these results indicated that alternative splicing of exons 3-5 generates functionally distinct hBMAL2 isoforms possessing high, medium, low, or no activity.
This conclusion was affirmed when we assessed the effects of alternative translation start site selection on the activation capacities of hBMAL2b, g, and i. Deletion of the first 37 amino acids from our hBMAL2b, g, and i clones placed the translation initiation sites of our hBMAL2b∆N, g∆N, and i∆N expression plasmids at the putative translation initiation site of exon 2 (Fig. 5A ).
This yielded hBMAL2b∆N and i∆N proteins identical to those previously reported as hMOP9-Long and hBMAL2 (no alphabetic suffix), respectively (13, 16) . Paired overexpression of mCLOCK with each of these combined splice and start site variants revealed that alternative translation initiation site usage does not significantly affect the activation capacities of mCLOCK:hBMAL2b, g, or i heterodimers (Fig. 5B-D) . That is, similar magnitudes of luciferase reporter gene transcription were observed for hBMAL2∆N proteins as for corresponding full length hBMAL2 proteins, independent of the promoter studied. Furthermore, amino acid sequences encoded by exon 1 and the first 80 bp of exon 2 (i.e. sequences untranslated when the translation initiation site of exon 2 is utilized) were not required for maximal hBMAL2 function.
Although a 4 kDa size difference between the Myc-tagged hBMAL2 and hBMAL2∆N proteins overexpressed in this work was confirmed by western blot (data not shown), the true translation 
Deletion of the C-Terminus of hBMAL2
The transcriptional activation domains of hARNT, mARNT2, and mARNT3 / mBMAL1 have been mapped to the C-termini of these class I bHLH-PAS proteins (10, (34) (35) (36) . To better characterize the functional domains of hBMAL2, we exploited the point mutation first identified in the clone hBMAL2b W309*. Introduction of this point mutation into wild type hBMAL2g and hBMAL2i cDNAs yielded hBMAL2g∆C and hBMAL2i∆C proteins complementary to hBMAL2b W309* / hBMAL2b∆C (Fig. 6A) . Paired overexpression of mCLOCK with each truncated splice variant revealed a distinct activation capacity for each resulting mCLOCK:hBMAL2∆C heterodimer that averaged from one third to one half that of the corresponding full length mCLOCK:hBMAL2 heterodimer (Fig. 6B-D) . Although transcriptional activation was reduced in the absence of the PAS-B and C-terminal domains of hBMAL2, these results indicated that the variable N-terminal, bHLH, and PAS-A domains of hBMAL2 together are sufficient to significantly induce luciferase reporter gene transcription in the presence of mCLOCK (P < 0.001 for each heterodimer).
Transcriptional Activation in the Presence of Multiple hBMAL2 Splice Variants
Alternative splicing has been identified as a mechanism by which both active and dominant negative transcription factors may be generated from the same gene (8). Thus we investigated the possibility that less active hBMAL2 isoforms may interact with more active hBMAL2 isoforms in a dominant negative fashion (Fig. 7) . Cotransfection of a constant, non-limiting mass of mCLOCK plasmid with varying quantities of hBMAL2b, g, or i plasmid revealed dose-dependent luciferase reporter gene transcription, thereby demonstrating strong correlation between mCLOCK:hBMAL2 heterodimer availability and hPAI-1 promoter activity. Similar results were obtained for mixtures that included hBMAL2b W309* (data not shown), indicating that deletion of the PAS-B and C-terminal domains of hBMAL2 via point mutation does not yield a dominant negative protein analogous to the mutant mCLOCK-∆19 (9, 19). In addition, hBMAL2f failed to inhibit gene transcription mediated by other mCLOCK:hBMAL2 heterodimers (data not shown).
Inhibition of mCLOCK:hBMAL2 Heterodimers by PER and CRY Proteins
Finally, we investigated the effects of alternative splicing of hBMAL2 on the abilities of mPER1, mPER2, mCRY1, and mCRY2 to inhibit mCLOCK:hBMAL2 mediated induction of hPAI-1 promoter activity (Fig. 8) . In fact, alternative splicing of hBMAL2 did not affect the functions of these inhibitors. Consistent with previous reports (21, 25), mCRY1 and mCRY2 exhibited greater inhibitory activities than mPER1 and mPER2. On average, mCLOCK:hBMAL2 heterodimers were inhibited with mCRY1 by 91%, with mCRY2 by 86%, with mPER1 by 53%, and with mPER2 by 78% (P < 0.001 for each inhibitory interaction). Similar results were obtained for hBMAL2b W309* (data not shown), indicating that the PAS-B and C-terminal domains of hBMAL2 are not required for inhibition by PER and CRY proteins. Also illustrated in Fig. 8 , neither mPER1,2 nor mCRY1,2 significantly affected hPAI-1 promoter activity in the absence of mCLOCK:hBMAL2 heterodimer overexpression.
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DISCUSSION
In this work, we identified four novel human BMAL2 transcripts that differed by alternative splicing within their N-terminal regions. Addition of these transcripts to the existing catalogue of hBMAL2 isoforms increased the total number of known hBMAL2 splice variants to nine. Considered together, hBMAL2 splice variants were each composed of a variable N-terminal region (exons 1-5) followed by thirteen invariant exons (exons 6-18) that, with the exception of hBMAL2f, encoded the defining bHLH, PAS-A, PAS-B, and C-terminal domains of hBMAL2.
Although the relative levels of native hBMAL2a-i proteins in vivo remain unknown, RT-PCR analysis revealed the predominant hBMAL2 transcripts in human tissues and primary cultures of human vascular smooth muscle and endothelial cells to be those encoding hBMAL2b, e, h, and i.
These most common hBMAL2 transcripts differed from each other either by exon 1 length or by deletion vs. insertion of exon 3 immediately prior to the bHLH domain encoded by exon 6.
Alternative splicing is not unique to hBMAL2. As an example from the circadian clock field, Drosophila clockwork is modulated by a thermosensitive splicing event in the 3' untranslated region of Period that ultimately enables flies to maintain daytime activity at low temperatures (26).
Alternative splicing also determines the sequences that immediately precede the bHLH domains of many class I bHLH-PAS proteins in addition to hBMAL2. Human and mouse ARNT1, as well as zebrafish ARNT2, are subject to deletion vs. insertion of an exon encoding 15 amino acids adjacent to their bHLH domains (11, 31, 37) . Mouse BMAL1 is subject to deletion vs.
insertion of an exon encoding 7 amino acids adjacent to its bHLH domain (36, 41). Rat BMAL2 is subject to splicing of an alternative exon orthologous to exon 3 of hBMAL2 (28).
Given such conservation of alternative splicing immediately preceding the bHLH domains of divergent species and duplicated genes, it is important to consider the functional consequences of We have shown that individual human tissues coincidently express multiple hBMAL2 splice variants. As both the total concentrations of hBMAL2 and the relative concentrations of specific hBMAL2 splice variants differ among tissues, it is reasonable for us to speculate that hBMAL2-dependent transcriptional activation also differs among tissues according to both total hBMAL2 expression and alternative splicing of expressed hBMAL2 transcripts. As we have demonstrated, co-expression of multiple hBMAL2 splice variants has an additive effect on the transcriptional activation of responsive genes. Although hBMAL2 splice variants with high, medium, low, or no activity neither synergize nor directly inhibit each other, their coincident formation in tissuespecific ratios may allow different tissues to regulate CLOCK:BMAL2 heterodimer function across a broad continuum of potential transcriptional activities.
Although light-responsive circadian oscillations in BMAL2 transcription have been reported for the zebrafish and chick (4, 29, 30) , no such oscillations have been observed yet for mouse BMAL2 (25, 28). As repeated sampling of human tissues was beyond the scope of this study, we cannot conclude at this time whether or not temporal variation exists among either total hBMAL2 levels or specific hBMAL2 isoform ratios in response to either the "ticking" of circadian clocks or other environmental stimuli. Nonetheless, alternative splicing is an intriguing mechanism by which different tissues may control the amplitudes of their circadian oscillators to Taken together, the results presented in this study not only contribute to our understanding of the functional domains of hBMAL2 but also establish alternative splicing of hBMAL2 as a potentially important regulatory mechanism controlling both central and peripheral circadian rhythms. 
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